Congratulations Tenaya Therapeutics on IPO Completion!

On July 30, 2021, Tenaya Therapeutics commenced trading on the Nasqaq market under the ticker symbol TNYA.

• August 16, 2022

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.

n July 2021, Tenaya Therapeutics announced its IPO of 13,800,000 shares of its common stock and trading on the Nasdaq. LS Associates worked with Tenaya Therapeutics and assisted in the process of preparing for their initial public offering.

LS Associates is proud to come alongside Tenaya as they revitalize heart disease treatment. Congratulations to our friends at Tenaya Therapeutics!

We are a member of the global LifeSci Partner platform that has been providing valuable executive advisory services since 2009.